anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A preparation for the treatment of hemophilia A inhibitor patients contains a protein or peptide having a specific Factor VIII:CAg activity of at least 0.5, preferably at least 1 VIII:CAg unit per mg protein, the ratio between the VIII:CAg activity and the VIII:C procoagulant activity being greater than 5:1, preferably greater than 10:1. A fragment of Factor VIII:C, which displays a doublet of a molecular weight of 80/77 kD in electrophoresis, is reactive hemophilia A inhibitor antibodies and has VIII:CAg activity. This fragment and more low-molecular fragments of Factor VIII:C are capable of neutralizing the coagulation inhibiting effect of all tested antibodies. Such fragments can therefore be used as active component in preparations for providing immunotolerance towards Factor VIII:C in high-dose treatment of inhibitor patients. The peptides are moreover useful as an immunosorbent in specific extracorporeal adsorption treatment of inhibitor patients. The inhibitor reactive peptides can e.g. be recovered from plasma fractions by affinity chromatography, hydrophobic interaction chromatography or cation exchange or they may by produced biosynthetically and recovered in a similar manner.
PURPOSE:To obtain easily stable tablets, by forming an additive and a chemical causing chemical reaction in contact in the state of powder separately into tablets to make them present in one dose package of divided packaging. CONSTITUTION:An additive and a chemical, e.g. an effervescent tablet, consisting of aspirin and an antacid, vitamin C and an antacid, an organic acid and a bicarbonate, causing chemical reaction in contact in the state of powder are separately formed into tablets, made present in one dose unit (in one dose package) of divided packaging and stabilized. The above-mentioned method is applicable to the method for tableting all the additives and chemicals causing chemical reactions by mutual contact. The additives and chemicals can be taken out at the same time for use due to the presence in one dose package, and the same effect of use as in two- or three-layer tablets, etc. can be expected. The method can be applied to all the industrial fields, e.g. medicines, foods, agricultural chemicals, fertilizers, etc.
Participants in this arm will undergo a conventional physical therapy program for 3 weeks (15 sessions) supervised by physiotherapists. Additionally, during each physical therapy session, participants will receive a 20-minute Virtual Reality (VR)-assisted hypnotherapy session using the HypnoVR software.
An additive 50 for use alone as a tablet or capsule or with a base product 54 to produce an enhanced product 52 that provides health benefits 34 to a person 20 who consumes or uses the additive 50, including stimulating naturally occurring enzymes in the person's body. The additive 50 has one or more hydrogenated substances 58, such as Erythritol 58a, Xylitol 58b, hydrogenated dihydromyricetin 58c and/or Quercetin dihydrate 58d, and the flavonoid Dihydromyricetin 14a. The flavonoid 14 may be extracted from a Vine Tea plant 17 and/or a plant chosen from the genus Hovenia,16, such as the Japanese raisin tree. The additive may also have one or more of a solvent 60, such as a bicarbonate compound 60a or an alcohol solvent 60b, a pH balancing acid 62 and/or preservatives 64. The base product 54 may be a liquid 66, solid 68, powder 70, chewable 72, pharmaceutical 74, cosmetic 76 or lotion or other applied product 78. The enhanced product 52 is a base product 54 that is enhanced by the additive.
A cosmetic facial cleanser and moisturizer primarily composed of water subjected to electrolysis. This water is the product of a multi-step process comprising a plurality of separate batch processes, wherein each successive process yields a product with greater bactericidal and moisturizing effects than the product yielded from the previous process. The first process comprises the passage of an electric current through water without the presence of electrolytes, which yields water with a lowered viscosity. The resulting water is then placed into a series of batch energizer reactors, wherein the water is successively irradiated with far infrared light in each batch reactor, each successive reactor yielding a product with greater aforementioned effects. Receivers at each batch reactor allow the water to be properly drained from the reactors. Additional cleansing agents may be added.
Background: Epistaxis is the most common emergent consultation to otolaryngology-head \& neck surgery (OHNS) and with 60% of the population having experienced an episode and 1.6 in 10,000 requiring hospitalization in their lifetime. In preliminary studies Floseal® (Baxter, USA) Hemostatic Matrix has shown efficacy in up to 80% of persistent anterior epistaxis. We sought to evaluate the clinical efficacy¬ and cost-effectiveness of Floseal® (Baxter, USA) compared to traditional nasal packing for persistent epistaxis.

Methods: A prospective, randomized controlled trial was conducted on all adult patients consulted to the OHNS service at the tertiary referral centers of the University of Alberta Hospital and Royal Alexandra Hospital for persistent epistaxis. Patients were randomized to the Floseal® (Baxter, USA) or traditional packing study arms. Our main clinical outcome measures were: 1) Hemostasis directly following treatment and at 48 hours post-treatment, and 2) self-reported patient comfort at 48 hours post-treatment. Further, trial data was used for a formal cost-effectiveness analysis to determine incremental cost-effectiveness ratio (ICER). Univariate sensitivity analysis and uncertainty analysis were performed.
Gastric emphysema is characterized by the presence of intramural gas in the stomach without bacterial infection. Due to its rarity, most reports on gastric emphysema have been limited to single-case studies, and this condition's clinical and endoscopic features have not been thoroughly investigated. In this study, we analyzed 45 patients with gastric emphysema from 10 institutions and examined their characteristics, endoscopic features, and outcomes. The mean age at diagnosis of gastric emphysema in our study population (35 males and 10 females) was 68.6 years (range, 14-95 years). The top five underlying conditions associated with gastric emphysema were the placement of a nasogastric tube (26.7%), diabetes mellitus (20.0%), post-percutaneous endoscopic gastrostomy (17.8%), malignant neoplasms (17.8%), and renal failure (15.6%). Among the 45 patients, 42 were managed conservatively with fasting and administration of proton pump inhibitors. Unfortunately, seven patients died within 30 days of diagnosis, and 35 patients experienced favorable recoveries. The resolution of gastric emphysema was confirmed in 30 patients through computed tomography (CT) scans, with a mean duration of 17.1 ± 34.9 days (mean ± standard deviation [SD], range: 1-180 days) from the time of diagnosis to the disappearance of the gastric intramural gas. There were no instances of recurrence. Endoscopic evaluation was possible in 18 patients and revealed that gastric emphysema presented with features such as redness, erosion, coarse mucosa, and ulcers, with fewer mucosal injuries on the anterior wall (72.2%), a clear demarcation between areas of mucosal injury and intact mucosa (61.1%), and predominantly longitudinal mucosal injuries on the stomach folds (50.0%). This study is the first English-language report to analyze endoscopic findings in patients with gastric emphysema.
BACKGROUND: Clinical findings and postoperative follow-up data on remnant gastric cancer (RGC) are limited due to its rarity. Additionally, the preoperative staging, radical surgery, and managing recurrence in RGC present significant clinical challenges.
METHODS: We analyzed the clinicopathological findings, adjuvant chemotherapy, and patterns of postoperative recurrence of 313 consecutive patients who underwent curative surgery for RGC at 17 Japanese institutions. This study investigated the optimal management of RGC and the impact of adjuvant chemotherapy (AC) on recurrence-free survival (RFS).
RESULTS: Pathological stages I, II, and III were observed in 55.9% (N = 175), 24.9% (N = 78), and 19.2% (N = 60) of the patients, respectively. The overall concordance rate between clinical and pathological T staging was 58.3%, with a clinical T4 sensitivity of 41.4% for diagnosing pathological T4. During the median follow-up period of 4.6 years, disease recurrence occurred in 24.3% of patients. Most recurrences (over 80%) occurred within 2.5 years, and 96.1% within 5 years after RGC surgery. Peritoneal recurrence was the most common in patients with advanced RGC, accounting for 14.1% in stage II and 28.3% in stage III. Multivariable regression analysis showed that AC was significantly associated with a longer RFS, with a hazard ratio of 0.45 (95% confidence interval: 0.26-0.76).
CONCLUSIONS: Our study underscores the importance of early detection, accurate preoperative staging, and postoperative surveillance in managing advanced RGC cases. Despite some limitations, our findings indicate that AC may provide survival benefits comparable to those seen in primary gastric cancer.
The invention discloses a traditional Chinese medicine preparation for treating hepatic stones and gall-stones. The traditional Chinese medicine preparation is prepared from the following traditional Chinese medicine preparation raw materials, by weight, 32-45 parts of common clubmoss herb, 30-39 parts of folium artemisiae argyi, 21-31 parts of a traditional Chinese medicine named after ermuning, 12-28 parts of fructus gleditsiae, 13-27 parts of hawthorn leaves, 9-17 parts of caulis sinomenii, 5-14 parts of dates, 3-7 parts of oriental wormwood and 5-10 parts of toosendan fruit. The traditional Chinese medicine preparation is reasonable in formula and is convenient and safe to take, no toxic or side effects are discovered, and clinic verification therapeutic effects are definite and substantial. After clinic observation for many years, the traditional Chinese medicine preparation has functions of nourishing yin, nourishing liver, nourishing yin to lessen fire, diminishing inflammation, nourishing gallbladder and discharging stones. The effective rate of treating hepatolithiasis is more than 99.0%. The traditional Chinese medicine preparation can be used for lowering postoperation residual stone rate, can prevent stone recurrence and has substantial effects aimed to pre-operation conditioning and postoperation consolidation. The traditional Chinese medicine preparation is low in preparation cost, no recurrence is generated after curing, pain of patients is relieved, and good economic benefits and social benefits are made.
PURPOSE: This study aimed to assess the feasibility of the Apple AirPods Pro with the headphone accommodation feature as a hearing assistive device for patients with mild to moderate hearing loss (HL).
MATERIALS AND METHODS: The study included a total of 35 participants with mild to moderate HL. To determine the degree of HL in the participants, a screening test using pure-tone audiometry was conducted prior to the main tests of functional gain, word recognition score (WRS), and sentence recognition in noisy environments. The study employed two hearing devices: the Bean (a personal sound amplification product, PSAP) and the AirPods Pro.
RESULTS: Regarding functional gain, there were no significant differences between the Bean and the AirPods Pro at all frequencies, except 8 kHz. In terms of WRS, both the Bean and the AirPods Pro had higher scores than the unaided condition. In sentence recognition, both the Bean and the AirPods Pro had higher scores than the unaided condition. During real-ear measurement, the Bean demonstrated consistent frequency responses, while the AirPods had a deviation exceeding 10 dB SPL at 6 kHz in the left ear. This deviation was absent for all other frequencies.
CONCLUSION: This study shows that the Apple AirPods Pro, with its headphone accommodation feature, performed similarly to a validated PSAP and improved hearing compared to unaided conditions.
OBJECTIVE: To compare early-onset sepsis (EOS) risk estimation and recommendations for infectious evaluation and/or empiric antibiotics using a categorical risk assessment versus the Neonatal Early-Onset Sepsis Calculator in a low-risk population.
STUDY DESIGN: Retrospective chart review of late preterm (≥350/7-366/7 weeks' gestational age) and term infants born at the Brooke Army Medical Center between January 1, 2012 and August 29, 2019. We evaluated those born via cesarean section with rupture of membranes (ROM) < 10 minutes. Statistical analysis was performed to compare recommendations from a categorical risk assessment versus the calculator.
RESULTS: We identified 1,187 infants who met inclusion criteria. A blood culture was obtained within 72 hours after birth from 234 (19.7%) infants and 170 (14.3%) received antibiotics per routine clinical practice, using categorical risk assessment. Respiratory distress was the most common indication for evaluation, occurring in 173 (14.6%) of patients. After applying the Neonatal Early-Onset Sepsis Calculator to this population, the recommendation was to obtain a blood culture on 166 (14%), to start or strongly consider starting empiric antibiotics on 164 (13.8%), and no culture or antibiotics on 1,021 (86%). Utilizing calculator recommendations would have led to a reduction in frequency of blood culture (19.7 vs. 14%, p < 0.0001) but no reduction in empiric antibiotics (14.3 vs. 13.8%, p = 0.53). There were no cases of culture-proven EOS.
CONCLUSION: This population is low risk for development of EOS; however, 19.7% received an evaluation for infection and 14.3% received antibiotics. Utilization of the Neonatal Early-Onset Sepsis Risk Calculator would have led to a significant reduction in the evaluation for EOS but no reduction in antibiotic exposure. Consideration of delivery mode and indication for delivery may be beneficial to include in risk assessments for EOS.
KEY POINTS: · Cesarean section with rupture of membranes at delivery confers low risk for EOS.. · Respiratory distress often triggers an EOS evaluation.. · Delivery mode should be considered in EOS risk..
The present invention relates to a preparation method of a naproxen slow releasing capsule preparation. The preparation method of the present invention comprises the following steps: hypromellose, sodium alginate and No. 3 resin of acrylic acid are added to naproxen raw material medicine; an obtained mixture is uniformly mixed; the No. 3 resin of acrylic acid, ethyl cellulose and diethyl phthalate are dissolved in ethanol; an obtained mixture and the obtained mixture are uniformly mixed to be granulated; after dryness, talcum powder is added, and an obtained product is encapsulated. The method of the present invention is simple and feasible. The effective blood drug level of the obtained product can be rapidly obtained, the effective blood drug level is kept stable, the dose of taking medicine is reduced, the side effect is reduced, and the variation range of peak concentration and valley concentration is small. After the product enters the stomach and the intestinal tract of a person, a gel frame is formed, the gel frame can prevent medicine from being quickly dissolved, the slow releasing purpose is obtained, and the product has no toxicity for a human body.
Methods and systems for assessing autism spectrum disorder (ASD) are described herein. Data identifying one or more behaviors associated with ASD may be received. A scenario specifying a plurality of different tasks may be received. An extended reality (XR) device may present and XR environment to a subject. The XR device may present, in the XR environment, a first task of the plurality of different tasks. Based on a subject interaction with one or more objects in the XR environment, interaction data may be calculated. Based on the interaction data, at least one second task may be selected from the plurality of different tasks. The at least one second task may be configured to train a different skill as compared to the first task. The XR environment may be modified to present the second task.
Absorption: The single-dose pharmacokinetic parameters of loxapine following administration of single doses of ADASUVE 10 mg in healthy adult subjects are presented in Table 3 and Figure 8. 

Administration of ADASUVE resulted in rapid absorption of loxapine, with a median time of maximum plasma concentration (T max) of 2 minutes. Loxapine exposure in the first 2 hours after administration (AUC 0-2h) was 66.7 ng∙h/mL for the 10 mg dose. As a consequence of the very rapid absorption of loxapine after oral inhalation, there is substantial variability in the early plasma concentrations of loxapine. The mean plasma loxapine concentrations following administration of ADASUVE were linear over the clinical dose range. AUC 0-2h, AUC inf, and C max increased in a dose-dependent manner. 

Figure 8. Mean Plasma Concentrations of Loxapine following Single-Dose Administration ADASUVE 10 mg in Healthy Subjects

Distribution: Loxapine is removed rapidly from the plasma and distributed in tissues. Animal studies following oral administration suggest an initial preferential distribution in the lungs, brain, spleen, heart, and kidney. Loxapine is 96.6% bound to human plasma proteins. 

Metabolism: Loxapine is metabolized extensively in the liver following oral administration, with multiple metabolites formed. The main metabolic pathways include: 1) hydroxylation to form 8-OH-loxapine by CYP1A2 and 7-OH-loxapine by CYP3A4 and CYP2D6, 2) N-oxidation to form loxapine N-oxide by flavanoid monoamine oxidases (FMOs), and 3) de-methylation to form amoxapine. Because there are multiple metabolic pathways, the risk of metabolic interactions caused by an effect on an individual isoform is minimal. For ADASUVE, the order of metabolites observed in humans (based on systemic exposure) was 8-OH-loxapine >> loxapine N-oxide, 7-OH-loxapine > amoxapine. Plasma levels of 8-OH-loxapine are similar to those of the parent compound. 

Excretion: Excretion occurs mainly in the first 24 hours. Metabolites are excreted in the urine in the form of conjugates and in the feces unconjugated. The terminal elimination half-life (T½) ranged from 6 to 8 hours. 

Transporter Interaction: In vitro studies indicated that loxapine was not a substrate for p-glycoprotein (P-gp): however, loxapine inhibited P-gp. 

Special Populations:

Pharmacokinetics in Smokers:  Loxapine exposures in nonsmokers and smokers are similar, with geometric mean ratios of 92%, 85%, and 99% for AUC 0-2h, AUC inf, and C max respectively. No dosage adjustment is recommended based on smoking status. 

Demographic Effects:  There were no clinically significant differences in loxapine pharmacokinetics following administration of ADASUVE in subgroups based on age, weight, body mass index, gender, or race.
One hour prior to procedure, subject to receive 30 mL of 0.5% ropivacaine injected into the nerve sheath of the femoral nerve at the level of the femoral triangle. Ultrasound guidance utilized for appropriate localization of the targeted nerve sheath for local infiltration. No nerve stimulators to be utilized during or after the procedure.
One week before the initiation of the study participants will be required to avoid consuming drugs, alcohol, cigarettes, probiotics, and any other food or liquid which could modify gut microbiota composition. For the baseline values, height, weight and sports performance test, of the participants will be collected. The same day, a strenuous exercise session will be performed in order to observe the variation of the intestinal damage marker (blood sample extraction just after finishing the strenous exercise session). 24 hours after that session sport performance tests will be conducted. Participants will then be randomly divided into two groups, one of which will take one probiotic capsule per day containing 10 billion colony-forming units (CFU) of Lactobacillus plantarum, and the other group will take one placebo capsule per day consisting of dextrose. The supplementation period will last 4 weeks.

After the supplementation period, the same process will be followed, with the same strenuous exercise session and immediate blood sampling to determine the effects of probiotics on the intestinal damage caused by exercise. 24 hours later, performance tests will be conducted to assess the effects of probiotics on sport performance.
BACKGROUND: Ileo-ileal knotting is a very rare cause of small bowel obstruction, and only a few reports have been published. Small bowel obstruction (SBO) is one of the most common emergency surgical conditions that require urgent evaluation and treatment and is one of the leading causes of emergency surgical admission. There are many causes of SBO that are known in general surgical practice, and these causes are different in the developing and developed worlds.
CLINICAL PRESENTATION: In this article, we present a case of acute gangrenous SBO secondary to ileo-ileal knotting in a 37-year-old Ethiopian female patient after she presented with severe abdominal cramp, vomiting, and abdominal distension of 4 hours duration. The patient was operated on intraoperatively; she had gangrenous small bowel obstruction caused by ileo-ileal knotting. Later, the patient was discharged and improved after 12 days of hospital stay.
CONCLUSION: Ileo-ileal knotting should always be considered in the differential diagnosis of acute small-bowel obstruction. The diagnostic difficulty and the need for urgent treatment of this condition to yield optimal results are discussed.
PURPOSE: A composition for suppressing differentiation and growth of adipocytes is provided to treat or prevent circulatory system disease or ischemic heart disease. CONSTITUTION: A composition for suppressing differentiation or growth of adipocytes contains 0.00001 to 15 weight% of chemerin. The adipocyte is human bone marrow mesenchymal stem cell. A pharmaceutical composition is used in the form of oral administration formulation or injection. The oral administration formulation is formulated in capsule, tablet, suspension, syrup or powder. A functional health food composition for preventing or treating diabetes, hyperlipidemia, hypercholesterolemia, circulatory system diseases contains 0.00001-10 weight% of chemerin. The health food is used in the form of caramel, chocolate, diet bar or snack. A cosmetic composition for treating obesity contains 0.00001-10 weight% of chemerin as an active ingredient. The cosmetic composition is used in the form of massage cream, body lotion, body cream, body oil, or body essence.
Patients with NSCLC will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX301. Phase 1b dose expansion will include 20 per-protocol treated patients, as defined above, in each of the two expansion cohorts.
Burnout, proposed by American psychologist Herbert Freudenberger in 1974, is defined as a syndrome resulting from chronic exposure to workplace stressors and the inability to successfully manage them. Subsequently, Maslach et al. considered burnout as the state of emotional exhaustion, depersonalization, and reduced personal accomplishment resulting from prolonged exposure to work-related stressors. In January 2022, the World Health Organization (WHO) included "burn-out" in the 11th Revision of the International Classification of Diseases (ICD-11) for the first time, officially recognizing it as a disease. Burnout is considered a syndrome resulting from chronic workplace stress that has not been successfully managed. Compared to other professions, doctors are at a higher risk of experiencing burnout. Burnout among medical professionals is closely related to job quality, doctor-patient relationships, and overall health. In 2022, 47% of 13,000 physicians in the United States reported experiencing burnout. Investigating whether burnout affects physical and mental health, thereby impacting the quality of healthcare, is essential.